menu
    • menu
    [{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Lyell Immunopharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Treg therapy","moa":"T cell","graph1":"Immunology","graph2":"Undisclosed","graph3":"Sonoma Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Lyell Immunopharma","highestDevelopmentStatusID":"1","companyTruncated":"Sonoma Biotherapeutics \/ Lyell Immunopharma"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"SBT-77-7101","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"Sonoma Biotherapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sonoma Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SBT115301","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Treg-based Cell Therapy","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Sonoma Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0.12,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Treg Cell Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sonoma Biotherapeutics","amount2":0.12,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Sonoma Biotherapeutics \/ Regeneron Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Sonoma Biotherapeutics

    Menu

    Sonoma Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treg Cell Therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : $120.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sonoma Biotherapeutics Receives $45M Regeneron Milestone

                            Details : The collaboration will bring together Regeneron’s VelociSuite technologies to discover, develop and commercialize engineered Treg therapies for autoimmune diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $75.0 million

                            September 04, 2024

                            Lead Product(s) : Treg Cell Therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : $120.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treg-based Cell Therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : $120.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell T...

                            Details : Regeneron and Sonoma will research and develop Treg-based Cell Therapies for ulcerative colitis, Crohn’s disease and two other undisclosed indications, through VelociSuite® technologies for the discovery and characterization of fully human antibodies ...

                            Brand Name : Undislcosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : $75.0 million

                            March 28, 2023

                            Lead Product(s) : Treg-based Cell Therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : $120.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SBT115301

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effec...

                            Details : SBT115301, is a biologic designed to eliminate highly activated effector T cells that are dominant in autoimmune and inflammatory disease, is CD2-binding fusion protein that resets microenvironment by selectively depleting and inactivating these Teff cel...

                            Brand Name : SBT115301

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 08, 2022

                            Lead Product(s) : SBT115301

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SBT-77-7101

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $265.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Sonoma Raises $265M in an Oversubscribed Series B Financing Towards a Cell Therapy for Autoimmune and Other In...

                            Details : SBT-77-7101, a novel CAR-based Treg cell therapy for patients with refractory rheumatoid arthritis. Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary Treg therapy and effector T cell cond...

                            Brand Name : SBT-77-7101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 04, 2021

                            Lead Product(s) : SBT-77-7101

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $265.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sonoma Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treg therapy

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Lyell Immunopharma

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Sonoma bags $40M to push Tregs for autoimmune, neuro diseases

                            Details : The series A funding is to advance regulatory T cell therapy in autoimmune and degenerative diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 06, 2020

                            Lead Product(s) : Treg therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Lyell Immunopharma

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth